RecruitingInterventionalNot ApplicableUpdated Dec 15, 2025
Safety and Efficacy of a Glaucoma Drug Delivery System | NCT00824720 | Trialant
CompletedInterventionalPhase 2Updated Mar 6, 2015
Safety and Efficacy of a Glaucoma Drug Delivery System
ClinicalTrials.gov ID
NCT00824720
Lead Sponsor
Vistakon PharmaceuticalsINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
55Actual
Last Update Posted
Mar 6, 2015Estimated
Start Date
Dec 2008
Primary Completion Date
Apr 2009Actual
Completion Date
Apr 2009Actual
Brief Summary
The purpose of this study is to evaluate the ocular safety and efficacy of a glaucoma drug delivery system in open-angle glaucoma or ocular hypertension.
Glaucoma, Open-Angle
Ocular Hypertension
High Dose Device
Low Dose Device
Placebo Device
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Man or woman 21 years of age or greater
must have open angle glaucoma or ocular hypertension.
Corrected visual acuity in each eye of 20/200 or better.
Exclusion Criteria:
Previous glaucoma intraocular surgery or refractive surgery.
Planned contact lens use during the study.
Clinically significant ocular or systemic disease that might interfere with the study.